Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 15/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11396433 | 0.71 | PDE2A (0.47) | PDE2A | |
| SCHEMBL18362225 | 0.66 | PDE2A (0.39) | PDE2A | |
| SCHEMBL18362090 | 0.65 | PDE2A (0.38) | PDE2AMAPK1 | |
| SCHEMBL18362093 | 0.64 | PDE2A (0.42) | PDE2A | |
| SCHEMBL11395847 | 0.64 | PDE5A (0.55) | PDE2AADORA3 | |
| SCHEMBL12415257 | 0.63 | APAF1 (0.33) | — | |
| SCHEMBL5989848 | 0.62 | KDM4E (0.37) | PDE2AMAPK1 | |
| SCHEMBL18362232 | 0.61 | PDE2A (0.48) | PDE2A | |
| SCHEMBL5863360 | 0.59 | PARP1 (0.38) | PDE2APARP1 | |
| SCHEMBL19398960 | 0.57 | PDE9A (0.47) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501699-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-08-06 | — | — | US | disclosed |
| US-8415309-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGMENT PTY LTD (AT) | 2013-04-09 | — | — | US | disclosed |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8119607-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-21 | — | — | US | disclosed |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122811-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | PDE2A 1206/4885ADORA3 85/4885HPGD 941/4885 |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | PDE2A 1206/4885ADORA3 85/4885HPGD 941/4885 |
| US-20130018013-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | PDE2A 1206/4885ADORA3 85/4885HPGD 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.